First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial
Key Points
Key points are not available for this paper at this time.
Abstract
Nct03875573.
Demander à l'IA
Like
Bookmark
Share
View Full Paper
Demander à l'IA
Like
Bookmark
Share
View Full Paper
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial | Synapse